| Literature DB >> 35080750 |
Jenny Lingman Framme1,2, Christina Lundqvist3, Anna-Carin Lundell3, Pauline A van Schouwenburg4, Andri L Lemarquis5, Karolina Thörn3, Susanne Lindgren5,3, Judith Gudmundsdottir5,6, Vanja Lundberg5,3, Sofie Degerman7,8, Rolf H Zetterström9,10, Stephan Borte11, Lennart Hammarström12, Esbjörn Telemo3, Magnus Hultdin7, Mirjam van der Burg4, Anders Fasth5, Sólveig Oskarsdóttir5, Olov Ekwall5,3.
Abstract
BACKGROUND: Population-based neonatal screening using T-cell receptor excision circles (TRECs) identifies infants with profound T lymphopenia, as seen in cases of severe combined immunodeficiency, and in a subgroup of infants with 22q11 deletion syndrome (22q11DS).Entities:
Keywords: 22q11.2 deletion syndrome; DiGeorge syndrome; T lymphopenia; TREC; long-term outcome; newborn screening; severe combined immunodeficiency
Mesh:
Substances:
Year: 2022 PMID: 35080750 PMCID: PMC9016018 DOI: 10.1007/s10875-021-01201-5
Source DB: PubMed Journal: J Clin Immunol ISSN: 0271-9142 Impact factor: 8.542
Characteristics of the study participants
| 1 | 1 | 20 | F | ASD VSD | Non-visible | Cleft palate Umbilical hernia | Prolonged | RSV# Prolonged viral Recurrent OM | Thyrotoxicosis with TSHR-Abs | MMR given at age 10 yrs | CMV+ EBV+ | ||
| 2 | 2 | 18 | F | IAA VSD | Non-visible | Neonatal | ID | VZV# Prolonged viral | No live vaccines given | CMV+ EBV+ | |||
| 3 | 5 | 12 | M | ASD PA | * | VFI | ADD ID | Prolonged viral | Milk protein allergy | CMV+ EBV+ | |||
| 4 | 5 | 23 | F | IAA ASD VSD | Non-visible | ID | Prolonged viral Recurrent OM Recurrent pneumonia | Hypothyroidism with TPO-Abs | CMV+ EBV+ | ||||
| 5 | 7 | 8 | M | VSD CoA | Non-visible | Polydactyly Inguinal hernia Scoliosis | Neonatal | ADHD ID | Pneumonia Recurrent parotitis Septicemia | CMV+ EBV- | |||
| 6 | 9 | 22 | F | VFI | RSV# | Ulcerative colitis | CMV+ EBV+ | ||||||
| 7 | 14 | 16 | M | ToF | Non-visible | Scoliosis | Depression Autism | RSV# Prolonged viral | CMV- EBV- | ||||
| 8 | 15 | 13 | F | IAA ASD VSD | Non-visible | VFI | Neonatal | Pneumonia | CMV- EBV- | ||||
| 9 | 15 | 16 | F | TA VSD | Non-visible | Renal agenesis Scoliosis | Neonatal | ID | Pneumonia Prolonged viral | Pollen allergy Asthma | CMV+ EBV- | ||
| 10 | 16 | 14 | M | VFI | ADHD | Prolonged viral Recurrent OM | Pollen allergy | CMV- EBV+ | |||||
| Median | 8.1 | 15.8 | 4 Significant viral 7 Prolonged viral 3 Recurrent OM 3 Significant bacterial 6 | CMV 7+ EBV 6+ | |||||||||
| Range | 1.2–16.0 | 8.1–22.5 | |||||||||||
| Number | 4 M, 6 F | 8 | 5 | 3 | 3 | ||||||||
| 11 | 43 | 23 | M | VFI Scoliosis Talipes equinovarus | ADD Autism OCD | RSV# Prolonged viral Pneumonia | CMV- EBV- | ||||||
| 12 | 46 | 15 | F | IAA VSD | Non-visible | Scoliosis | Neonatal | ADD ID | Pneumonia | CMV- EBV- | |||
| 13 | 54 | 15 | F | VFI | ID ADHD | Recurrent OM | CMV- EBV+ | ||||||
| 14 | 54 | 8 | M | VSD PA | Non-visible | Polycystic kidney Undescended testis | Neonatal | VZV# Prolonged viral | CMV- EBV+ | ||||
| 15 | 54 | 23 | F | ToF PS | * | VFI Imperforate anus | RSV# Recurrent pneumonia Prolonged viral | Asthma | CMV- EBV+ | ||||
| 16 | 71 | 17 | F | VFI Scoliosis Vertebral anomaly | ID | Coeliac disease | Asthma | CMV- EBV+ | |||||
| 17 | 72 | 11,5 | M | VSD | Non-visible | ID | RSV# Pneumonia | Asthma | CMV- EBV+ | ||||
| 18 | 72 | 12 | F | IAA VSD ASD | Non-visible | Cleft palate Multicystic kidney | Neonatal | ADHD ID | RTI# | CMV- EBV+ | |||
| 19 | 74 | 23 | F | VFI Cleft palate Scoliosis | Pneumonia Viral Meningitis# | CMV+ EBV- | |||||||
| 20 | 96 | 16 | F | VSD | Hypoplastic | Clinodactyly | ID | Recurrent OM | Asthma | No MMR given | CMV+ EBV+ | ||
| Median | 62.5 | 15.8 | 6 Significant viral 3 Prolonged viral 2 Recurrent OM 5 Significant bacterial 4 | CMV 2+ EBV 7+ | |||||||||
| Range | 43.0–96.0 | 7.7–23.1 | |||||||||||
| Number | 3 M, 7 F | 6 | 3 | 1 | 4 | ||||||||
| Median | n.a. | 15.5 | 1 Significant viral 1 Prolonged viral 1 Significant bacterial 1 | 1 Coeliac disease | CMV 6+ EBV2+ | ||||||||
| Range | 9.2–22.2 | ||||||||||||
| Number | 4 M, 6 F | 4 | |||||||||||
NBS, newborn screening; 22q11Low, individuals with 22q11.2 deletion syndrome and low levels of TRECs upon NBS; 22q11Normal, individuals with 22q11.2 deletion syndrome and normal levels of TRECs upon NBS; F, female; M, male; ASD, atrial septal defect; VSD, ventricular septal defect; IAA, interrupted aortic arch; PA, pulmonary atresia; CoA, aortic coarctation; ToF, Tetralogy of Fallot; TA, truncus arteriosus; VFI, velopharyngeal insufficiency; ID, intellectual disability; ADD, attention deficit disorder; ADHD, attention deficit hyperactivity disorder; OCD, obsessive compulsive disorder; RSV, respiratory syncytial virus; OM, otitis media; VZV, varicella zoster virus; RTI, respiratory tract infection; CMV+, anti-CMV IgG >15 AU/ml; EBV+, anti-EBV IgG S/CO >1 to capsid and/or to nuclear antigen. *Data not available. #Requiring hospitalization
Fig. 1Primary outcome variables at follow-up. a The absolute counts of TRECs in whole blood. Absolute counts (b) and proportions (c) of T-helper lymphocytes (CD4), CD4 naïve cells and CD4 memory cells. Absolute counts (d) and proportions (e) of cytotoxic T lymphocytes (CD8), CD8 naïve cells and CD8 memory cells. The definitions of the cell types are provided in Supplementary Table S1. Results are shown as individual values for the healthy controls (gray dots), 22q11Normal individuals (blue squares), and 22q11Low individuals (red triangles). Lines denote medians and whiskers indicate the interquartile ranges. P value summary indicated on each graph: *P ≤ .05, **P ≤ .01, ***P ≤ .001
Fig. 2T-cell receptor repertoires and relative telomere lengths. TRBV gene usage in naïve T-helper lymphocytes (CD4 naïve) (a) and naïve cytotoxic T lymphocytes (CD8 naïve) (b). The TRBV genes are ordered from most-frequently used (left) to least-frequently used (right) in the 22q11Low group. Usage rates of the most frequent TRBV genes are presented in an inset to the far right. Only unique sequences (as defined by TRBV gene usage and amino acid sequence of the CDR3) were used for the T-cell receptor repertoire analysis. Tree plots representing the diversity and clonality of CD4 naïve cells (c) and CD8 naïve cells (d) in the 22q11Low individuals (left), the healthy control matched for age and gender (right), and the matched 22q11Normal individual (middle). The box size is proportional to the extent of V and J gene usage. Major TRBV genes are indicated on each tree plot, whereas TRBJ genes are identified by the color code at the bottom left. Clonality scores of the CD4 naïve and CD8 naïve cell subsets (e). Relative telomere lengths (RTL) in the naïve and memory subsets of CD4, naïve and memory CD8, and B lymphocytes (CD19) (f). Results are shown as individual values for the healthy controls (gray dots), 22q11Normal individuals (blue squares), and 22q11Low individuals (red triangles). Information on missing data is provided in Supplementary Table S3. Lines denote medians and whiskers indicate the interquartile ranges. P value summary indicated on each graph: *P ≤ .05, **P ≤ .01, ***P ≤ .001
Fig. 3T- and B-lymphocyte subpopulations and immunoglobulin and cytokine levels. a Proportions of T-helper lymphocyte subsets (Th1, Th2 and Th17, Treg naïve, Treg memory). b Proportions of B-lymphocyte subsets (CD19 naïve, IgD+ IgM+ memory, IgM+ only memory, and class-switched). The definitions of the cell types are provided in Supplementary Table S1. c Serum concentrations of IgG, IgA, and IgM. d Plasma concentrations of cytokines. #All cytokine concentrations are presented as pg/ml, with the exception of CRP, which is presented in mg/L. IL, Interleukin; TSLP, thymic stromal lymphopoietin; IFN, interferon. Results are shown as individual values for the healthy controls (gray dots), 22q11Normal patients (blue squares), and 22q11Low patients (red triangles). Information on missing data is provided in Supplementary Table S3. Lines denote medians and whiskers indicate the interquartile ranges. P value summary indicated on each graph: *P ≤ .05, **P ≤ .01, ***P ≤ .001.
Fig. 4Multivariate discriminant analysis (DA) based on the immunological data and clinical data at follow-up. a OPLS-DA score plot showing healthy controls (gray dots), 22q11Normal (blue squares), and 22q11Low (red triangles) individuals, respectively. OPLS-DA column loading plots depicting the associations between the X-variables and the following groups: 22q11Low and healthy controls (b); 22q11Normal and healthy controls (c); and 22q11Low and 22q11Normal (d). The X-variables represented by a bar (light grey) pointing in the same direction as a group (dark grey bar) are positively associated with that group, whereas variables pointing in the opposite direction are inversely related. The larger the bar and the smaller the error bar, the stronger is that variable´s contribution to the model. All variables included in the model are listed in Supplementary Table S3. Only the X-variables with the strongest contributions to the model are shown and variable influence on projection (VIP) thresholds are indicated.